TABLE 3.
Univariate and multivariate analysis for overall survival of cytoplasmic CAIX protein expression and clinicopathological characteristics in ER‐negative cohort (n = 191).
| Clinicopathological characteristics | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95% CI) | p | HR (95% CI) | p | |
| Age (≤ 50/> 50 years) | 1.69 (1.06–2.67) | 0.026* | 1.92 (1.01–3.67) | 0.047* |
| Tumour size (mm) (≤ 20/21–50/> 50) | 1.82 (1.26–2.63) | 0.001* | 1.46 (0.77–2.77) | 0.247 |
| Grade (I/II/III) | 1.11 (0.72–1.70) | 0.651 | — | — |
| Involved lymph node (negative/positive) | 2.13 (1.38–3.27) | < 0.001* | 1.97 (0.89–4.35) | 0.094 |
| PR status (negative/positive) | 0.49 (0.12–2.03) | 0.332 | — | — |
| Her—2 status (negative/positive) | 1.06 (0.67–1.66) | 0.807 | — | — |
| Ki67 index (low/high) | 1.04 (0.66–1.65) | 0.871 | — | — |
| Lymphatic vessel invasion (no/yes) | 3.29 (1.88–5.77) | < 0.001* | 2.17 (1.01–4.65) | 0.046* |
| Blood vessel invasion (no/yes) | 3.38 (1.81–6.31) | < 0.001* | 3.02 (1.45–6.29) | 0.003* |
| Tumour necrosis (low/high) | 1.67 (0.94–2.97) | 0.079 | — | — |
| Klintrup‐Mäkinen grade (low/high) | 0.85 (0.64–1.14) | 0.275 | — | — |
| CD68+ (low/moderate/high) | 0.67 (0.48–0.94) | 0.022* | 0.66 (0.45–0.97) | 0.034* |
| CD8+ (low/moderate/high) | 0.59 (0.42–0.82) | 0.002* | 0.75 (0.48–1.15) | 0.182 |
| CD138+ (low/moderate/high) | 1.26 (0.92–1.72) | 0.151 | — | — |
| Tumour stroma percentage (low/high) | 1.81 (1.18–2.77) | 0.006* | 2.41 (1.27–4.58) | 0.007* |
| Tumour budding (low/high) | 2.01 (1.28–3.18) | 0.003* | 0.91 (0.44–1.87) | 0.801 |
| Adjuvant chemotherapy (no/yes) | 0.84 (0.54–1.29) | 0.424 | — | — |
| Adjuvant radiotherapy (no/yes) | 1.06 (0.69–1.62) | 0.804 | — | — |
| Cytoplasmic CAIX (low/high) | 1.69 (1.09–2.59) | 0.015* | 2.45 (1.28–4.67) | 0.007* |
*Statistically significant p value < 0.05.